Reeferman Genetics Pink Kush, STRONG Medicine. We never stop hearing great reviews from both growers and tokers alike when it comes to our Reeferman Genetics Pink Kush, available as feminized seeds. Looking at this tasty pile of frosty beautifuo buds, it's not hard to tell why!
The legalization of marijuana has been moving at a breakneck speed in the past 20 years. More and more americans are becoming in favor of legalization every year.
See the informational graphics below:
Prime Minister Justin Trudeau says that when his late brother Michel was charged with pot possession, his father's resources, legal network and connections helped make the charge "go away," and that he will introduce a "process" to help other Canadians with pot-related charges after recreational marijuana becomes legal.
Trudeau made the comments at a town hall hosted by Vice Media, during which the prime minister was asked by a member of the audience who had been charged with pot possession what Trudeau would say to someone in his position.
The prime minister answered the question by relating the story of how his late brother had been in a terrible car accident while driving back to Ontario from the West Coast.
When the police arrived at the scene, they found a couple of joints in the wreckage and charged Michel with possession of marijuana.
"When he got back home to Montreal, my dad said, 'OK, don't worry about it.' He reached out to his friends in the legal community, got the best possible lawyer and was very confident that he was going to be able to make those charges go away," Trudeau said.
"We were able to do that because we had resources, my dad had a couple of connections, and we were confident that my little brother wasn't going to be saddled with a criminal record for life."
Trudeau went on to say how people from minority communities, or without the finances or connections to make a pot possession charge go away are treated unfairly under the current system, when "Canada is supposed to be fair for everybody."
“The acceptance received from our inaugural year was much more than anticipated. It was an experiment with tremendous results. This second year, we would like to focus on growing this expanding industry that is just in its initial phase.”Omero, El Farmero
Omero el Farmero would like to welcome you. In April 16 and 17 of 2016, we witnessed a historic event in the Colombian Cannabis industry. We strive to continue to contribute with everything that we have: with passion, discipline, love, and knowledge so that the local atmosphere can keep growing and prospering and we would love for you to be a part of that. In 2016, we gathered 40 exhibitors and more than 2600 individuals during our one day trade show event on Sunday April 17, 2016.
May 28 & 29, 2017
+90 Stands | International Artists | Medicinal Forums | Activities | Food | Fair
Learn more at copaelcopo.com > >
The most important international cannabis fair will return and open its doors so that we can all live unforgettable moments and continue writing our own history. After the first fair in 2016, we strive to make the next one in 2017 with an even more solid proposal and an even bigger and expanded market. We will live this experience in the same place where we grew the initial seeds of success, which is an outdoor and scenic location with more than 10,000 square meters that include private parking, security, tranquility, and the marvelous eucalyptus that illuminate El Copo.Read more: El Copo, the Colombian Cannabis Cup
TORONTO, ON--(Marketwired - April 10, 2017) - Today, Canabo Medical Inc. (TSX VENTURE: CMM) (OTCQB: CAMDF) ("Canabo" or the "Company") released the results of a new, landmark observational study that connects doctor-supervised medical cannabis treatments to a sharp drop in benzodiazepine reliance among Canadian patients.
Research conducted over the past year revealed that 40 per cent of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. That percentage increased to 45 per cent within a year of cannabis treatment. The findings were announced by Dr. Neil Smith during a presentation at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) event in Toronto.
Canabo, which operates 15 cannabinoid clinics across Canada under the brand CMClinics, partnered with a consortium of medical research experts to analyze data from more than 1,500 patients with the aim of understanding how cannabis interacts with or lessens the need for pharmaceutical treatments. Preliminary findings in late 2016 indicated a downward trend in benzodiazepine use -- a trend that was confirmed after additional investigation and included in the Reduction of Benzodiazepine Use in Patients Prescribed Medical Marijuana report. The team responsible for the peer-reviewed report has shared their findings with several Canadian medical journals and details are expected to soon appear in the Dalhousie Medical Journal.
In Canada, 10 per cent of the general population use benzodiazepines daily, with common side-effects such as sedation, dizziness, drowsiness, unsteadiness, headache and memory impairment. Long-term benzodiazepine use is also associated with complications including problems with concentration, tolerance, addiction and overdose.Read full article: Milestone study shows dramatic reduction in pharmaceutical reliance among Canadian medical cannabis patients
About Canabo Medical Inc.
Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada's largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo has 15 clinics across Canada with several additional locations set to open in 2017.
Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.